CA2833706C — Quinazoline derivatives for the treatment of cancer diseases
Assigned to Boehringer Ingelheim International GmbH · Expires 2014-10-21 · 12y expired
What this patent protects
The present invention relates to the use of quinazolines of formula (I), (see formula I) wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
USPTO Abstract
The present invention relates to the use of quinazolines of formula (I), (see formula I) wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.